In this video, Dr Sara Tolaney underscores the positive overall survival outcomes from the monarchE trial, reinforcing the impact of adjuvant abemaciclib plus endocrine therapy in high-risk, hormone receptor (HR)-positive/HER2-negative early breast cancer, while also noting the sustained 5-year benefits observed with ribociclib and nonsteroidal aromatase inhibitors in the NATALEE trial.